Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.60 |
| ▸ | MMP13 | P45452 | 7/20 | 0.52 |
| ▸ | TNKS | O95271 | 1/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.50 |
| ▸ | TYMS | P04818 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.42 |
| ▸ | MMP10 | P09238 | 2/20 | 0.40 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8202010 | 0.81 | MMP13 (0.55) | PARP1MMP13TNKSTNKS2TYMS | |
| SCHEMBL8194247 | 0.81 | PARP1 (0.64) | PARP1MMP13TYMSPIN1 | |
| SCHEMBL689302 | 0.79 | PARP1 (0.58) | PARP1MMP13TNKSTNKS2 | |
| SCHEMBL6988205 | 0.79 | DYRK1A (0.42) | PARP1PIN1 | |
| SCHEMBL27683279 | 0.76 | PIN1 (0.43) | PARP1MMP13TNKSTNKS2TYMS | |
| SCHEMBL27683285 | 0.76 | PIN1 (0.40) | PARP1MMP13PIN1 | |
| SCHEMBL20339497 | 0.76 | PARP1 (0.64) | PARP1TNKSTNKS2 | |
| SCHEMBL27683281 | 0.76 | MMP13 (0.45) | PARP1MMP13PIN1 | |
| SCHEMBL29902989 | 0.76 | PARP1 (0.64) | PARP1TNKSTNKS2 | |
| SCHEMBL50874 | 0.76 | MMP13 (0.43) | MMP13TNKSPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| CN-101351453-A | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2009-01-21 | — | — | CN | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| WO-2008063668-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| CN-1976907-A | Heterocyclic amide compound and use thereof as an MMP-13 inhibitor | TAKEDA PHARMACEUTICAL (JP) | 2007-06-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PARP1 156/4885MMP13 1/4885TNKS 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.